Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

The Cooper Companies, Inc.

35 indications, side-by-side phase, drug & LoA

$67.88

+0.37 (+0.55%)

C 52Pipeline Score MedTech · Commercial
Market Cap
12.20 B
EPS
2.03
P/E Ratio
30.96 $
Value Trade
241.13 M
SEC Financials
Q2 2026

  • Dilution Risk

    35%

  • Revenue

    1.08 B

  • R&D Expenses

    42.50 M

  • Total Assets

    12.48 B

  • Total Liabilities

    4.24 B

  • Equity

    8.24 B

  • D/E Ratio

    12,345

3.37 %
Week
-7.28 %
1 Month
-25.13 %
3 Month
-12.79 %
6 Month
-35.96 %
5 Year
773.72 %
All Time
Cash Data
Stable

  • Cash Position

    139.00 M

  • Monthly Burn

    10.33 M

  • Runway

    13.3 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Jun 5, 2026
Overview
Volume
1.97 M
52 Week Range
58.89 - 89.83
% held by Insiders
0.67 %
% held by Institutions
105.76 %
Enterprise Value
14.58 B
Total Shares
195.17 M
Short %
2.73 %
Float Shares
190.49 M
Company Description
HQ: 6101 BOLLINGER CANYON ROAD, SA...
Employees:15,000
https://www.coopercos.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C52
Pipeline Score
$1.6B
Pipeline Value
Valuation Signal
10
Drugs Scored
0.4x
rNPV / MCap
Top 76%
Mid Cap
(rank 218 of 905)
Percentile Rank
The Cooper Companies, Inc. carries a moderate pipeline score (52/100), with $1.9B risk-adjusted pipeline value, led by Normal saline ,Control in Migraine Headache (Phase 3), across $93B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Normal saline ,Control
Unknown		Migraine HeadachePhase 3NCT0293306046% $744M COMPLETED 50 - -Sep 1, 2017 -Jul 15, 2019
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in COO
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
COO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COO
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
COO Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
COO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest The Cooper Companies, Inc. (COO) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How COO ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Bone Disorders #1 of 6 N/A Buprenorphine + Hydromorphone
SYK ·dev ZBH ·dev SNN
—0.88 LEADER
Brain Tumors #18 of 45 PHASE 2 Pre-radiation temozolomide.
NVCR JAZZ DAWN
$3.55B 0.88 FOLLOWER